[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100428209":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":51,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":19,"enrollmentInfo":76,"targetDuration":19,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Cardiac MRI, ECG and Blood Biomarkers","Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.",[12],"Diagnostic Test: Cardiac MRI, ECG\u002FHolter and Blood Biomarkers",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Cardiac MRI, ECG\u002FHolter and Blood Biomarkers","Cardiac MRI including T1\u002FT2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Kate Hanneman","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","416-323-6400","5521","kate.hanneman@uhn.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University Health Network","RECRUITING","Toronto","Ontario","M5G 2C4","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-79.39864,43.70643,{"lat":43,"lon":42},[46],{"name":47,"role":26,"phone":27,"phoneExt":28,"email":48},"Kate Hanneman, MD","Kate.Hanneman@uhn.ca",{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[52,54,56,58,60,62,64],{"name":53,"class":6},"Vancouver General Hospital",{"name":55,"class":6},"The Cleveland Clinic",{"name":57,"class":6},"Icahn School of Medicine at Mount Sinai",{"name":59,"class":6},"IRCCS Policlinico S. Donato",{"name":61,"class":6},"Alberta Health services",{"name":63,"class":6},"Libin Cardiovascular Institute of Alberta",{"name":65,"class":66},"Vancouver Coastal Health","OTHER_GOV","100428209","fabry-cardiomyopathy-identification-of-early-myocardial-structural-and-tissue-abnormalities-using-multiparametric-mri-100428209",false,"NCT04856059","Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI","FIESTA-MRI","Inclusion Criteria:\n\n* Fabry disease;\n* Age ≥ 18 years.\n\nExclusion Criteria:\n\n* History of myocardial infarction;\n* Contraindication to MRI.","ALL","18 Years",{"count":77,"type":78},300,"ESTIMATED","INTERVENTIONAL",[81],"NA","This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.",[84],"Fabry Disease",[86,87,88,89,90,91],"Fabry disease","Fabry cardiomyopathy","cardiac MRI","CMR","T1 mapping","T2mapping","2026-04-13",{"date":94,"type":95},"2026-04-16","ACTUAL",{"date":97,"type":95},"2021-06-15",{"date":99,"type":78},"2029-03-31",{"name":5,"class":6},1]